In the HER2CLIMB-05 trial, 55% of patients with ER-positive tumors did not receive concurrent endocrine therapy despite study protocol allowances. Dr. Hamilton noted that those who received endocrine therapy achieved much longer progression-free survival, highlighting a crucial treatment opportunity during chemotherapy de-escalation.
Despite initial concerns that combining pertuzumab and tucatinib would exacerbate severe diarrhea, grade 3 diarrhea increased by only 2% over placebo. Rather than gastrointestinal issues, elevated liver function tests occurred in approximately 25% of patients and served as the leading driver of dose holds, reductions, and treatment discontinuations.
Although the DESTINY-Breast09 trial omitted a maintenance phase following trastuzumab deruxtecan and pertuzumab, Dr. Hamilton notes oncologists will likely transition patients off therapy upon reaching maximal response. Clinicians expect to integrate tucatinib maintenance without randomized data to support long-term quality of life.
